Contrast-enhanced ultrasound exams detecting residual tumor blood flow can accurately predict how effective transarterial chemoembolization is in the treatment of hepatocellular carcinoma. The study had no false-negative results, and the one false positive came from an exam administered just one day after treatment. Ultrasound exams administered from two days to one month after treatment provided treatment results usually available only after three months using CT or MRI.
Contrast-enhanced ultrasound exams detecting residual tumor blood flow can accurately predict how effective transarterial chemoembolization is in the treatment of hepatocellular carcinoma. The study had no false-negative results, and the one false positive came from an exam administered just one day after treatment. Ultrasound exams administered from two days to one month after treatment provided treatment results usually available only after three months using CT or MRI.
Dr. Yuko Kono of the radiology department at the University of California, San Diego and colleagues published the study in the Journal of Vascular and Interventional Radiology in January 2007. They used contrast-enhanced ultrasound on 33 patients to detect blood flow in a total of 42 tumors.
Experienced radiologists performed phase-inversion low-mechanical-index real-time and intermittent imaging after injecting 0.5 to 2 mL contrast medium. They were blinded to all other imaging findings. Twenty-nine exams were performed within two weeks of transarterial chemoembolization, and the rest were performed within one month.
The results of the ultrasound exams were later compared with established methods of determining the efficacy of treatment. A total of nine tumors were dropped from the study because final outcome of treatment was not available, either because patients were lost to follow-up or they died without autopsy. Three more tumors were re-treated before final outcome of the first treatment was established.
This left a total of 33 tumors in the study. Histology determined the effectiveness of treatment on nine of these tumors, angiograms provided results for 14 tumors, and tumor growth was sufficient indication for two more. CT and MRI studies more than six months after treatment provided results for eight tumors.
All but one contrast-enhanced ultrasound exam matched the results of more established methods for determining effectiveness of treatment, but ultrasound provided those results more quickly. The one false-positive result was from an exam given within 24 hours of transarterial chemoembolization.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Finds Transvaginal Ultrasound Unreliable for Detecting Endometrial Cancer in Black Patients
July 3rd 2024Utilizing a threshold of less than 5 mm of ultrasound-measured endometrial thickness, the authors of a new study noted an 11.4 percent false-negative probability for endometrial cancer in Black patients.
New Study Shows Non-Radiologists Interpreting 28 Percent of Imaging for Medicare Patients
June 28th 2024While radiologists interpreted approximately 99 percent of all non-cardiac CT, MRI and nuclear medicine studies in hospital and emergency department settings for Medicare beneficiaries, new research shows significantly less radiologist review of cardiac imaging and office-based imaging.
FDA Clears Pocket-Sized ECG System and AI Technology for Detection of Cardiac Conditions
June 27th 2024Using a reduced leadset and deep neural network algorithms trained on more than 175 million electrocardiograms, the KAI 12L technology reportedly detects up to 35 cardiac determinations, including acute myocardial infarction.